Minimum clinically important difference (MCID) on the Unified Wilson Disease Rating Scale (UWDRS) Part III: results from the Phase 3 FoCus Trial
Objective: Minimum clinically important differences (MCID) on the Unified Wilson Disease Rating Scale (UWDRS) Part III were estimated using data from a phase III trial…Free water neuro-imaging changes as the biomarker in new diagnosis of Wilson’s disease
Objective: The bi-tensor free water imaging may provide more specific information in detecting microstructural brain tissue alterations than conventional single tensor diffusion tensor imaging. The…D-penicillamine induced myasthenia gravis – the possible complication of Wilson’s disease treatment.
Objective: D-penicillamine (DPA) belongs to the most frequently used drugs in Wilson’s disease (WD) treatment. Despite the effectiveness in WD treatment, DPA could be involved in many…Wilson disease: a single-center study from Tunisia
Objective: We aimed to describe different clinical and radiological presentations of WD and insist on the necessity of early diagnosis to ensure therapeutic efficiency. Background:…Throat Clearing tics In Wilson’s Disease- An Unusual Manifestation
Objective: To report unusual presentation of throat clearing tics in a 15 year old Indian girl with Wilson’s disease (WD). Background: WD is one of…Deterioration in Wilson’s Disease despite treatment. Are the neuroimaging findings useful as prognostic factor?
Objective: To describe the neuroimaging findings and their importance in the prognosis during the treatment. Additionally, to describe the state of art of the treatment.…Impact of ALXN1840 on the neurological symptoms of Wilson disease: secondary outcomes of a phase 2, open-label, single-arm study
Objective: To evaluate neurological efficacy outcomes of ALXN1840 treatment in adults with Wilson disease (WD) from a phase 2, open-label, single-arm study (NCT02273596). Background: WD…Long term follow-up of Wilson disease patients in Poland. Report from the national reference centre.
Objective: We present seven decades of experience of a single reference centre covering most adult Wilson disease (WD) patients in Poland. Background: WD is a rare…D-penicillamine induced lupus erythematosus – the complication of Wilson’s disease treatment – a case report.
Objective: Wilson’s disease (WD) is an inherited disorder of copper metabolism with copper accumulation in different organs and clinical symptoms related to the affected organs…Cooper-deficiency myeloneuropathy in Wilson´s Disease as a result of D-penicillamine treatment: A case report
Objective: To present a case of subacute combined degeneration of the spinal cord secondary to iatrogenic copper deficiency as a result of D-penicillamine therapy. Background:…